openPR Logo
Press release

Antisense Oligonucleotide Therapeutics Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies

08-29-2025 06:46 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Antisense Oligonucleotide Therapeutics Pipeline Outlook

DelveInsight's, "Antisense Oligonucleotide Therapeutics Pipeline Insight 2025," report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Antisense Oligonucleotide Therapeutics pipeline landscape. It covers the Antisense Oligonucleotide Therapeutics pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Antisense Oligonucleotide Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Antisense Oligonucleotide Therapeutics Research. Learn more about our innovative pipeline today! @ Antisense Oligonucleotide Therapeutics Pipeline Outlook [https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Antisense Oligonucleotide Therapeutics Pipeline Report

* On 27 August 2025, Laboratoires Thea conducted a Phase 2b study is to evaluate the safety and tolerability of ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.
* DelveInsight's Antisense Oligonucleotide Therapeutics pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Antisense Oligonucleotide Therapeutics treatment.
* The leading Antisense Oligonucleotide Therapeutics Companies such as Ionis Pharmaceuticals, Secarna Pharmaceuticals, Aro Biotherapeutics, NeuBase Therapeutics, Bio-Path Holdings, Inc., Scopus Biopharma, Dyne Therapeutics, CAMP4 Therapeutics, Pulmotect, GeneTx Biotherapeutics, Aligos Therapeutics, WaVe Life Sciences and others.
* Promising Antisense Oligonucleotide Therapeutics Pipeline Therapies such as Bepirovirsen, QR-421a, SB012, Sepofarsen, QR-110, PGN-EDO51, GSK3228836 and others.

Stay informed about the cutting-edge advancements in Antisense Oligonucleotide Therapeutics treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Antisense Oligonucleotide Therapeutics Clinical Trials Assessment [https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Antisense Oligonucleotide Therapeutics Emerging Drugs Profile

* Cobitolimod: InDex Pharmaceuticals

Cobitolimod is part of InDex Pharmaceuticals' DNA-based ImmunoModulatory Sequence (DIMS) platform. It is administered locally in the large intestine, where the substance binds to Toll-like receptor 9 (TLR9) present inside immune cells as well as on the surface of epithelial cells. The binding triggers the cells to product anti-inflammatory cytokines, agents that play an important role in reducing the inflammation and healing the wounds in the large intestine caused by UC. It is currently being evaluated in Phase III stage of development of Ulcerative colitis.

* Prexigebersen: Bio-Path Holdings

Prexigebersen (previously BP 100-1-01) is a neutral-charge, liposomal-delivered antisense cancer drug. It is designed to inhibit protein synthesis of Grb2 (growth factor receptor bound protein 2). Bio-Path is currently evaluating prexigebersen in Phase II program for the treatment of acute myeloid leukemia (AML). Prexigebersen has received orphan drug designation from the FDA and from the European Medicines Agency for AML.

The Antisense Oligonucleotide Therapeutics Pipeline Report provides insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of Antisense Oligonucleotide Therapeutics with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Antisense Oligonucleotide Therapeutics Treatment.
* Antisense Oligonucleotide Therapeutics Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Antisense Oligonucleotide Therapeutics Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Antisense Oligonucleotide Therapeutics market.

Learn more about Antisense Oligonucleotide Therapeutics Drugs opportunities in our groundbreaking Antisense Oligonucleotide Therapeutics research and development projects @ Antisense Oligonucleotide Therapeutics Unmet Needs [https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Antisense Oligonucleotide Therapeutics Companies

Ionis Pharmaceuticals, Secarna Pharmaceuticals, Aro Biotherapeutics, NeuBase Therapeutics, Bio-Path Holdings, Inc., Scopus Biopharma, Dyne Therapeutics, CAMP4 Therapeutics, Pulmotect, GeneTx Biotherapeutics, Aligos Therapeutics, WaVe Life Sciences and others.

Antisense Oligonucleotide Therapeutics pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical.
* Molecule Type

Antisense Oligonucleotide Therapeutics Products have been categorized under various Molecule types such as

* Monoclonal Antibody
* Peptides
* Polymer
* Small molecule
* Gene therapy
* Product Type

Discover the latest advancements in Antisense Oligonucleotide Therapeutics treatment by visiting our website. Stay informed about how we're transforming the future of Musculoskeletal @ Antisense Oligonucleotide Therapeutics Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the Antisense Oligonucleotide Therapeutics Pipeline Report

* Coverage- Global
* Antisense Oligonucleotide Therapeutics Companies- Ionis Pharmaceuticals, Secarna Pharmaceuticals, Aro Biotherapeutics, NeuBase Therapeutics, Bio-Path Holdings, Inc., Scopus Biopharma, Dyne Therapeutics, CAMP4 Therapeutics, Pulmotect, GeneTx Biotherapeutics, Aligos Therapeutics, WaVe Life Sciences and others.
* Antisense Oligonucleotide Therapeutics Pipeline Therapies- Bepirovirsen, QR-421a, SB012, Sepofarsen, QR-110, PGN-EDO51, GSK3228836 and others.
* Antisense Oligonucleotide Therapeutics Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Antisense Oligonucleotide Therapeutics Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Antisense Oligonucleotide Therapeutics Pipeline on our website @ Antisense Oligonucleotide Therapeutics Emerging Drugs and Companies [https://www.delveinsight.com/sample-request/antisense-oligonucleotide-therapeutics-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Antisense Oligonucleotide Therapeutics: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Late Stage Products (Phase III)
* Cobitolimod: InDex Pharmaceuticals
* Mid Stage Products (Phase II)
* Prexigebersen: Bio-Path Holdings
* Early stage products (Phase I/II)
* ALG-020572: Aligos Therapeutics
* Inactive Products
* Antisense Oligonucleotide Therapeutics Key Companies
* Antisense Oligonucleotide Therapeutics Key Products
* Antisense Oligonucleotide Therapeutics- Unmet Needs
* Antisense Oligonucleotide Therapeutics- Market Drivers and Barriers
* Antisense Oligonucleotide Therapeutics- Future Perspectives and Conclusion
* Antisense Oligonucleotide Therapeutics Analyst Views
* Antisense Oligonucleotide Therapeutics Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=antisense-oligonucleotide-therapeutics-pipeline-outlook-2025-clinical-trial-studies-ema-pdma-fda-approvals-moa-roa-nda-ind-and-companies]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/antisense-oligonucleotide-therapeutics-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antisense Oligonucleotide Therapeutics Pipeline Outlook 2025: Clinical Trial Studies, EMA, PDMA, FDA Approvals, MOA, ROA, NDA, IND, and Companies here

News-ID: 4163924 • Views:

More Releases from ABNewswire

Stud Service Company Sets the Standard for Smarter HVAC Solutions
Stud Service Company Sets the Standard for Smarter HVAC Solutions
Stud Service Company, based in Chesapeake, VA, sets the standard for smarter HVAC solutions, offering expert installation, repair, and maintenance for residential and commercial systems. With certified technicians, the company emphasizes long-term comfort, energy efficiency, and system durability. From AC repair to furnace replacement and water heater services, Stud Service Company ensures dependable performance and year-round comfort for customers. Chesapeake, VA - August 29, 2025 - Home and business owners seeking
State Approved Continuing Education Launches Express Certificate Processing Option
State Approved Continuing Education Launches Express Certificate Processing Opti …
State Approved Continuing Education, based in Abbott, TX, has launched an express certificate processing service for professionals needing fast license renewals. The service accelerates the final step of its online workflow-register, learn, and certify-by delivering certificates within 24-48 hours. Supporting trades like electricians, HVAC, and cosmetology, this new rush option ensures compliance and convenience for busy professionals across Texas. Abbott, TX - August 29, 2025 - State Approved Continuing Education has
US Specialty Coatings Expands Excellence in Athletic Field Marking with Precision Paints and Striping Solutions
US Specialty Coatings Expands Excellence in Athletic Field Marking with Precisio …
US Specialty Coatings, headquartered in Alpharetta, GA, reaffirms its leadership in the athletic field marking with premium paints and precision striping machines. Serving schools, pro teams, and municipalities, the company offers durable, vibrant paints, advanced marking robots, and custom stencils. Their solutions cover sports fields, traffic marking, and recreational facilities, delivering innovation, safety, and unmatched reliability nationwide. Alpharetta, GA - August 29, 2025 - US Specialty Coatings, a leading innovator in
Real Estate Listing Agent in Huntington Beach, CA, Advises on Strategic Timing as Median Home Prices Reach $1.365M
Real Estate Listing Agent in Huntington Beach, CA, Advises on Strategic Timing a …
Huntington Beach, CA - The coastal Orange County housing market continues demonstrating resilience with median home prices reaching $1.365 million, representing a 4.6% year-over-year increase. Current market conditions show homes averaging 41 days on market, indicating a more balanced environment compared to previous years. This shift presents opportunities and challenges for buyers and sellers navigating the luxury coastal landscape. Scott J. Miller, real estate agent in Huntington Beach, CA [https://www.abnewswire.com/pressreleases/best-real-estate-selling-agent-in-huntington-beach-ca-lists-gated-midcentury-ranch-in-one-of-the-most-soughtafter-neighborhoods_753949.html], brings

All 5 Releases


More Releases for Therapeutic

Exosome Therapeutic Market : Detailed Overview
Introduction: The exosome therapeutic market is a rapidly emerging segment in the field of regenerative medicine and drug delivery. Exosomes are extracellular vesicles naturally released by cells that play a crucial role in cell communication and genetic material transfer. They have gained attention for their potential applications in treating various diseases, including cancer, neurodegenerative disorders, and cardiovascular conditions. As a novel therapeutic platform, exosomes provide significant advantages such as low immunogenicity,
Parkinson's Disease Therapeutic Market Hope for Patients: The Parkinson's Diseas …
Parkinson's Disease Therapeutic Market worth $6.51 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Parkinson's Disease Therapeutic Market - (By Drugs (Carbidopa-levodopa, Dopamine agonists, Mao-b inhibitors, COMT inhibitors, Anticholinergics, Others), By Distribution Channel (Hospital pharmacy, Retail pharmacy, Online pharmacy), By Brand (Branded, Generics), By Route of Administration (Oral, Injectable, Intestinal Infusion, Subcutaneous, Others)),
Global Remote Therapeutic Monitoring Market
According to a new market research report published by Global Market Estimates, the Global Remote Therapeutic Monitoring Market is projected to grow at a CAGR of 17.4% from 2023 to 2028. Medsien, Intellihinc, Zimmer Biomet, Owlytics Healthcare, Limber Health, Medistics, RxCap, Propeller Health, HealthArc, CENSON Health, and B Castle Smith & Co., are some of the key players in the remote therapeutic monitoring market. Browse 147 Market Data Tables and 115
Europe Digital Therapeutic (DTx) Market
Europe Digital Therapeutic (DTx) Market report provides information about the industry, including valuable Analysis and Detailed study. This research study explores the Global Europe Digital Therapeutic (DTx) Market in detail such as industry chain structures, raw material suppliers, with manufacturing. The Europe Digital Therapeutic (DTx) market examines the primary segments of the market. This intelligent study provides historical data from forecast.It also provides the details such as whether the customers
Recombinant Therapeutic Antibodies and Proteins Market continues to expand with …
Recombinant therapeutic protein drugs are an important class of medicines, which helps patients in need of novel therapies. Recently approved recombinant protein therapeutics have been developed to treat a wide variety of clinical indications, including cancers, inflammation/autoimmunity, genetic disorders, and exposure to infectious agents. The latest advancements in protein-engineering technologies have allowed drug manufacturers and developers to adjust desirable functional characteristics of proteins of interest maintaining product efficacy. Protein-based therapies
Therapeutic Vaccine Market 2020 - 2028 Top Companies Agenus Inc., Argos Therapeu …
This detailed market study covers therapeutic vaccine market growth potentials which can assist the stake holders to understand key trends and prospects in therapeutic vaccine market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The